Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ACADIA Pharmaceuticals Inc.

https://www.acadia-pharm.com/

Latest From ACADIA Pharmaceuticals Inc.

Vifor/Angion Collaboration On Rocky Ground As ANG-3777 Phase III Trial Fails In Kidney Transplant Patients

Vifor and Angion’s ANG-3777 has failed in a Phase III trial for kidney transplant patients at risk of delayed graft function less than a year after the companies sealed a $80m licencing deal for the product. As focus shifts to another rare nephrological indication, analysts express skepticism.

Clinical Trials Companies

B-Ingelheim India Chief On Strategy, Jardiance Challenge, Gender Balance In Pharma

Boehringer Ingelheim’s Country Managing Director for India Vani Manja outlines how she expects to shape the German group’s growth trajectory in the country, while also dealing with the unexpected pre-expiry challenge to the Jardiance patent. The executive also discusses her personal career journey, learnings from her prior role in the US and gives advice to women executives seeking to move up to the higher echelons of the corporate world.

Commercial Intellectual Property

Pfizer COVID Shot: Unanimous Vote Obscures Reservations About Vaccinating All Children 5-11

Many of US FDA's outside vaccine advisors wanted to wait for more data before widespread inoculations of kids 5-11, but felt some high-risk populations should get access to vaccine right away. They urged CDC to provide additional guidance on which children should be targeted.

Advisory Committees Vaccines

‘Skinny Label’ Case Gives Brands A ‘Blueprint’ To Alter Use Codes In Patent Litigation

Federal Circuit ruling in GSK v. Teva shows brands can broaden a use code to include other patented indications years into litigation, AAM attorney says. The case is ‘scarier’ for biosimilar makers since they must market their products, Teva lawyer notes.

Advertising, Marketing & Sales Biosimilars
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Receptor Technologies
    • CerSci Therapeutics
UsernamePublicRestriction

Register